Issued on behalf of PlantX Life Inc.
VANCOUVER – USA News GroupNews Commentary – With over 100 million Americans facing obesity and rates rising globally, it’s no surprise that analysts at SNS Insider predict the Weight Loss Drugs Market will rapidly grow at a massive 43.73% CAGR through 2032. As one of the fastest-growing sectors in pharmaceuticals, nearly one in four employers are likely to begin covering anti-obesity medications within the next year. Health and wellness companies are swiftly adapting, with recent market developments coming from: PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF), Herbalife Ltd. (NYSE: HLF), WW International, Inc. (NASDAQ: WW), Medifast, Inc. (NYSE: MED), and Amgen Inc. (NASDAQ: AMGN).
The article continued: According to Morgan Stanley, the global market for blockbuster obesity drugs could increase by more than 15x over the next five years, as their benefits expand beyond weight loss, with expected implications for consumer goods and longevity. With big pharma players entering the race, new weight loss drugs could be developed even faster.
PlantX Life Inc. Announces Joint Venture with LIV3 to Launch SugarShield Supplement Addressing the USD 5.24 Billion Weight Loss Management Supplement Market
PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF), a pioneer in building strong communities and operating innovative experiential online and in-store platforms that make it easier for individuals to lead happier and healthier lives, today announced a joint venture with LIV3, founded by Christopher Mearns, to launch their SugarShield supplement. Targeting the rapidly expanding US$5.24 billion Weight Loss Management Supplement Market, PlantX will handle the design of SugarShield’s branding and packaging, while also building an intuitive e-commerce platform for its launch. PlantX will lead all marketing efforts, including leveraging its proprietary SEO strategies to boost brand visibility, while Mearns will manage product supply. The joint venture agreement includes an equal 50/50 profit-sharing arrangement.
“As the weight loss supplement market continues to expand, driven by excitement around the popularity in products once designed for treating effects of type 2 diabetes, we at PlantX see this as an opportunity to offer a plant-based alternative without the synthetic properties,” said Lorne Rapkin, CEO of PlantX. “We believe Chris Mearns has developed what can be considered ‘nature’s Ozempic’ with SugarShield. We’re confident that the branding, packaging, and website we create will reflect the innovation and benefits of this product, making it stand out in the growing weight management market.”
The joint venture with PlantX equips LIV3 with the tools to build a strong online presence for SugarShield. Leveraging PlantX’s branding and digital expertise, the supplement will be able to reach health-conscious consumers worldwide.
LIV3 highlights that SugarShield is formulated to boost energy, reduce cravings, and support weight management—all without restrictive diets. After years of development, Christopher Mearns has crafted a formula offering the health benefits of a sugar-free diet while easily fitting into daily routines. Mearns explains that the supplement lowers uric acid, a key factor in cellular stress, promoting improved metabolic health.
“With LIV3’s SugarShield, consumers can detox from the negative effects of fructose without changing their diet,” said Christopher Mearns, founder of LIV3. “This supplement improves energy levels through enhanced mitochondrial function, supports glucose utilization, and increases insulin sensitivity, leading to weight loss and improved metabolic conditions. We’ve already begun designing the branding and packaging with the PlantX team, and we’re very excited about the upcoming launch. Simply put, our metabolic health was broken by daily fructose intake, and luteolin is the answer because it blocks the harmful effects of fructose.”
A key figure in this collaboration is Dr. Paul Gross, a long-standing member of PlantX’s medical panel. Dr. Gross has been instrumental in validating the scientific foundation of SugarShield, ensuring its formulation is both effective and backed by research. His expertise has been vital in establishing confidence in SugarShield’s potential benefits, enabling PlantX and LIV3 to launch this innovative product with confidence in its efficacy.
This partnership supports PlantX’s ongoing commitment to expanding its plant-based wellness offerings while capitalizing on the rapidly growing health and supplement markets.
CONTINUED… Read this and more news for PlantX Life at:https://usanewsgroup.com/2024/10/08/from-plants-to-plates-wellness-delivered/
In other industry developments and happenings in the market this week include:
Herbalife Ltd. (NYSE: HLF), a premier health and wellness company community and platform, recently set a new GUINNESS WORLD RECORDS title for the largest high-intensity interval training class (multiple venues), featuring more than 4,900 Herbalife independent distributors and fitness enthusiasts in a shared mission to celebrate the power of community, health, and wellness.
For weight loss, Herbalife offers several Healthy Weight products in its portfolio, including its own GLP-1 Nutrition Companion products, which it launched back in February. The 2024-launched new range of food and supplement product combos fueled by Herbalife’s protein shakes, are intended to support the nutritional needs of individuals on GLP-1 and other weight-loss medications, such as Ozempic and/or Mounjaro.
“Weight-loss drugs curb your appetite, so people taking medications like GLP-1 Agonist may have difficulty getting all the macronutrients, micronutrients or physical activity they need for optimal muscular, cardiovascular and brain health,” said Kent Bradley, M.D., MBA, MPH, chief health and nutrition officer at Herbalife. “Individuals taking these medications should supplement with products that help meet these needs and focus on making foundational lifestyle changes to achieve sustainable weight loss.”
WW International, Inc. (NASDAQ: WW), better known as WeightWatchers, recently announced the addition of compounded GLP-1 into its offering, broadening eligible members’ access to clinical weight management interventions that are underpinned by the comprehensive, science-backed, behavioral and lifestyle support that has helped millions o fpeople reach and sustain their weight goals.
“At WeightWatchers, we have always combined proven science and personalized support to help our members achieve meaningful, lasting results,” said Tara Comonte, Interim CEO of WeightWatchers. “With the addition of compounded semaglutide, we are expanding our offering to include a clinical weight management solution that is both accessible and affordable. This launch is the culmination of extensive research and rigorous work by our team to ensure that we are offering the highest quality care — reaffirming the trust we’ve built over six decades as the leader in weight management.”
Medifast, Inc. (NYSE: MED), an international manufacturer and vendor of weight loss, weight management and healthy living products, was originally a skeptic of GLP-1 medications, but has begun to evolve and adapt towards the growing availability and acceptance of this form of treatment, by now including access to GLP-1 medications where clinically appropriate.
"Our holistic approach, encompassing nutrition, personalized coaching, a supportive community, and access to a clinician through our collaboration with telehealth provider, LifeMD, positions us uniquely to support those who are interested in weight loss medications as well as those who are transitioning off a medical regimen, or those who choose to pursue more traditional weight loss methods,” said Dan Chard, Chairman and CEO of Medifast. “Our mission today, much like it has been over the last 40 years, is to help our customers create lifestyle changes and establish healthy habits, and we are developing new plans and products to aid individuals in achieving healthier lifestyles. We believe we are more relevant than ever in today’s environment and are well positioned to shape the future of health and wellness, impacting millions of lives."
Amgen Inc. (NASDAQ: AMGN), a global therapeutics developer and manufacturer, recently spoke at the Morgan Stanley Global Healthcare Conference stating that it is “rapidly” advancing its anti-obesity asset MariTide through Phase II, after which it plans to initiate a “robust, wide-ranging Phase III clinical program” for the candidate, which is an injectable bispecific molecule that works by simultaneously activating the GLP-1 receptor while also blocking the GIP receptor.
“We look forward to generating data that will show what we can achieve in patients that are obese or living with overweight and what we can do in that context for patients that are at high risk of heart disease, renal disease, liver disease,” said Robert Bradway, CEO of Amgen.
MariTide is thought to promote the release of insulin from the pancreas, suppress appetite and improve various other metabolic parameters. Back in February, Amgen’s MariTide published Phase I results in the journal Nature Metabolism, demonstrating 14.5% body weight loss by day 85, compared to the placebo group that gained 1.5% body weight in the same time frame.
Source: https://usanewsgroup.com/2024/10/08/from-plants-to-plates-wellness-delivered/
CONTACT:
USA NEWS GROUP
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for PlantX Life Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of PlantX Life Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of PlantX Life Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of PlantX Life Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of PlantX Life Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
